The financials
Alkermes plc by the numbers
Alkermes plc (ALKS) reported revenue of $393M in Q1 2026 (quarter ended March 31, 2026), up 28% from the same quarter a year earlier. That came with a gross margin of 84% and net loss of $66M. For the full year FY2025, revenue was $1.48B (−5.2% year on year) and net income $242M. Its largest product in 2026-Q1 was Vivitrol at $112M, 27% of the disclosed total, just ahead of Aristada And Aristada Initio at 23%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $393M | $307M | +28% |
| Gross profit | $331M | $257M | +29% |
| Operating income | −$48M | $14M | to a loss |
| Net income | −$66M | $22M | to a loss |
| Diluted EPS | −$0.40 | $0.13 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Vivitrol | $112M | 27% |
| Aristada And Aristada Initio | $94M | 23% |
| LYBALVI | $92M | 22% |
| Manufactured Product And Royalty | $55M | 13% |
| LUMRYZ | $39M | 9.5% |
| Royalty | $18M | 4.3% |
| Manufacturing | $4.1M | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $415.0M (-3.0%)
LYBALVI grew +32% year on yearManufacturing -32% year on year
Segment Latestquarter on quarteryear on year
- Vivitrol$112.4M$112.4MQoQ -7.2%year on year +11%-7.2%+11%
- Aristada And Aristada Initio$93.8M$93.8MQoQ -4.3%year on year +28%-4.3%+28%
- LYBALVI$92.4M$92.4MQoQ -6.0%year on year +32%-6.0%+32%
- Manufactured Product And Royalty$54.8M$54.8MQoQ -29%year on year -12%-29%-12%
- LUMRYZ$39.5M$39.5MQoQ -year on year ---
- Royalty$18.0M$18.0MQoQ -40%year on year +1.4%-40%+1.4%
- Manufacturing$4.1M$4.1MQoQ +16%year on year -32%+16%-32%
- Research And Development--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #21 of 28 by Smart Score